Inhibition of procollagen C-proteinase: Fibrosis and beyond

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 8, 2004, Pages 1185-1197

  Turtle, Eric D ^a   Ho, Wen Bin ^a  

^a FIBROGEN INC   (United States)

Author keywords

Bone morphogenetic protein 1; Fibrosis; Mammalian tolloid; Procollagen C proteinase; Tolloid like protein

Indexed keywords

4 MERCAPTOANILINE; ANTIFIBROTIC AGENT; ASTACIN; BIGLYCAN; BONE MORPHOGENETIC PROTEIN; CARBOXYLIC ACID DERIVATIVE; CGS 27023A; CHORDIN; COLLAGEN; COLLAGEN FIBRIL; ENZYME INHIBITOR; GLUTAMIC ACID DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; ISOENZYME; KALININ; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MATRIX PROTEIN; MYOSTATIN; OXIDOREDUCTASE; PHOSPHINIC ACID DERIVATIVE; PRINOMASTAT; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; SULFONAMIDE; THIOL DERIVATIVE; TYROSINE HYDROXAMIC ACID; UK 383367; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE DISEASE; CANCER INVASION; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FIBROSIS; HUMAN; IC 50; MEDICAL LITERATURE; MOLECULAR BIOLOGY; MUSCULOSKELETAL DISEASE; NONHUMAN; PATENT; PATHOLOGY; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SCAR FORMATION; SQUAMOUS CELL CARCINOMA; WOUND HEALING IMPAIRMENT;

EID: 4344600469     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.8.1185     Document Type: Review

References (64)

1. SCOTT IC, BLITZ IL, PAPPANO WN et al.: Mammalian BMP-1/tolloid-related metalloproteinases, including novel family member mammalian tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis. Dev. Biol. (1999) 213(2):283-300.
2. TAKAHARA K, LYONS GE, GREENSPAN DS: Bone morphogenetic protein-1 and a mammalian tolloid homologue (mTld) are encoded by alternatively spliced transcripts which are differentially expressed in some tissues. J. Biol. Chem. (1994) 269(51):32572-32578.
3. PROCKOP DJ, SIERON AL, LI S: Procollagen N-proteinase and procollagen C-proteinase. Two unusual metalloproteinases that are essential for procollagen processing probably have important roles in development and cell signaling. Matrix Biol. (1998) 16:399-408.
4. LAPIERE CM, LENARERS A, KOHN ID: Procollagen peptidase: an enzyme excising the coordination peptides of procollagen. Proc. Natl. Acad. Sci. USA (1971) 68:3054-3058.
5. HOJIMA Y, VAN DER REST M, PROCKOP DJ: Type I procollagen carboxy-terminal proteinase from chick embryo tendons. Purification and characterization: J. Biol. Chem. (1985) 260:15996-16003.
6. KESSLER E, ADAR R: Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55kD enhancer glycoprotein. Eur. J. Biochem. (1989) 186:115-121.
7. Ll S, SIERON AL, FERTALA A, HOJIMA Y, ARNOLD WV: The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Proc. Natl. Acad. Sci. USA (1996) 93:5127-5130.
8. TAKAHARA K, BREVARD R, HOFFMAN GG, SUZUKI N, GREENSPAN DS: Characterization of a novel gene product (mammalian tolloid-like) with high sequence similarity to mammalian tolloid/bone morphogenetic protein-1. Genomics (1996) 34:157-165.
9. WOZNEY JM, ROSEN V, CELESTE AJ et al.: Novel regulators of bone formation: molecular clones and activities. Science (1988) 242:1528-1534.
10. KESSLER E, TAKAHARA K, BINIAMINOV L, BRUSEL M, GREENSPAN DS: Bone morphogenetic protein-1: the Type I procollagen C-proteinase. Science (1996) 271:360-362.
11. WOLFMAN NM, MCPHERRON AC, PAPPANO WN et al.: Activation of the latent myostatin by the BMP/tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. USA (2003) 100(26):15842-15846.
12. MULLINS MC: Holy tolloido - tolloid cleaves SOG/chordin to free DPP/BMPs. Trends Genet. (1998) 14(4):127-129.
13. HARTIGAN N, GARRIGUE-ANTAR L, KADLER KE: Bone morphogenetic protein-1 (BMP-1) identification of the minimal domain structure for procollagen C-proteinase activity. J. Biol. Chem. (2003) 278(20):18045-18049.
14. GARRIGUE-ANTAR L, BARKER C, KADLER KE: Identification of amino acid residues in bone morphogenetic protein-1 important for procollagen C-proteinase activity. J. Biol. Chem. (2001) 276(28):26237-26242.
15. BOND JS, BEYNON RJ: The astacin family of metalloendopeptidases. Protein Sci. (1995) 4:1247-1261.
16. GOMIS-RUTH FX, STOCKER W, HUBER R, ZWILLING R, BODE W: Refined 1.8 Å X-ray crystal structure of Astacin, a zinc-endopeptidase from the crayfish Astacus astacus L. J. Mol. Biol. (1993) 229:945-968.
17. GRAMS F, DIVE V, YIOTAKIS A, YIALLOUROS I, VASSILIOU S, ZWILLING R et al.: Structure of astacin with transition-state analogue inhibitor. Nat. Struct. Biol. (1996) 3:671-675.
18. LEE S, SOLOW-CORDERO DE, KESSLER E, TAKAHARA K, GREENSPAN DS: Transforming growth factor-β regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes. J. Biol. Chem. (1997) 272(30):19059-19066.
19. LEIGHTON M, KADLER KE: Paired basic/furin-like proprotein convertase cleavage of pro-BMP-1 in the trans-Golgi Network. J. Biol. Chem. (2003) 278(20):18478-18484.
20. GARRIGUE-ANTAR L, HARTIGAN N, KADLER KE: Post-translational modification of bone morphogenetic protein-1 is required for secretion and stability of the protein. J. Biol. Chem. (2002) 277(45):43327-43334.
21. STEIGLITZ BM, KEENE DR, GREENSPAN DS: PCOLCE2 encodes a functional procollagen c-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1. J. Biol. Chem. (2002) 277(51):49820-49830.
22. RICARD-BLUM S, BERNOCCO S, FONT B et al.: Interaction properties of the procollagen c-proteinase enhancer protein shed light on the mechanism of stimulation of VMP-1. J. Biol. Chem. (2002) 277(37):33864-33869.
23. UZEL MI, SCOTT IC, BABAKHANLOU-CHASE H et al.: Multiple bone morphogenetic protein-1 related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J. Biol. Chem. (2001) 276(25):22537-22543.
24. STEIGLITZ BM, AYALA M, NARAYANAN K, GEORGE A, GREENSPAN DS: Bone Morphogenetic protein-1/tolloid-like proteinases process dentin matrix protein. J. Biol. Chem. (2004) 279(2):980-986.
25. PAPPANO WN, STEIGLITZ BM, SCOTT IC, KEENE DR, GREENSPAN DS: Use of Bmp 1/tll1 doubly homozygous null mice and proteomics to identify an validate in vivo substrates of bone morphogenetic protein 1/tolloid-like metalloproteinases. Mol. Cell. Bio. (2003) 23(13):4428-4438.
26. RATTENHOLL A, PAPPANO WN, KOCH M et al.: Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen. J. Biol. Chem. (2002) 277(29):26372-26378.
27. MEDECK RJ, SOSA S, MORRIS N, OXFORD JT. BMP-1 mediated proteolytic processing of alternatively spliced isoforms of collagen type XI. Biochem J. (2003) 376:361-368.
28. SIERON AL, TRETIAKOVA A, JAMESON BA et al.: Structure and function of Procollagen C-proteinase (m Tolloid) domains determined by protease digestion, circular dichroism, binding to procollagen Type I, and computer modeling. Biochemistry (2000) 39:3231-3239.
29. KESSLER E, FICHARD A, CHANUT-DELALANDE H, BRUSEL M, RUGGIERO F: Bone morphogenetic protein-1 (BMP-1) mediates C-terminal processing of procollagen V homotrimer. J. Biol Chem. (2001) 276(29):27051-27057.
30. 2pro-α 2(V) collagen heterotrimer by bone morphogenetic protein-1 and furin-like proprotein convertases. J. Biol. Chem. (2002) 277(7):5596-5602.
31. SCOTT IC, IMAMURA Y, PAPPANO WN et al.: Bone morphogenetic protein-1 processes probiglycan. J. Biol. Chem. (2000) 275(39):30504-30511.
32. WADDINGTON RJ, ROBERTS HC, SUGARS RV, SCHONHERR E: Differential roles for small leucine-rich proteoglycans in bone formation. Eur. Cell. Mater. (2003) 6:12-21.
33. SVENSSON L, HEINEGARD D, OLDBERG A: Decorin-binding sites for collagen Type I are mainly located in leucine-rich repeats 4-5. J. Biol. Chem. (1995) 270(35): 20712-20716.
34. AMANO S, SCOTT IC, TAKAHARA K et al.: Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5γ2 chain. J. Biol. Chem. (2000) 275(30):22728-22735.
35. QIN C, BRUNN JC, COOK RG et al.: Evidence for the proteolytic processing of dentin matrix protein 1. J. Biol. Chem. (2003) 278(36):34700-34708.
36. BLADER P, RASTEGAR S, FISCHER N, STRAHLE U: Cleavage of the BMP4 antagonist chordin by zebrafish tolloid. Science (1997) 278:1937-1940.
37. ZAVOICO GB: New targets for the treatment of pathological fibrosis, an unmet clinical need. Drug Market Dev. (1999) 10(1):2-10.
38. BITTERMAN PB, HENKE CA: Fibroproliferative disorders. Chest (1991) 99(3):81S-84S.
39. TRANSQUILLO RT, MURRAY JD: Continuum model of fibroblast-driven wound contraction: inflammation-mediation. J. Ther. Biol. (1992) 158:135-172.
40. MAST BA, DIEGELMANN R, KRUMMEL TM, COHEN IK: Scarless wound healing in mammalian fetus. Surg. Gynecol. Obstet. (1992) 174:441-451.
41. VEITCH DP, NOKELAINEN P, MCGOWAN KA et al.: Mammalian tolloid metalloproteinase, and not matrix metalloprotease 2 or membrane Type 1 metalloprotease, process laminin-5 in keratinocytes and skin. J. Biol. Chem. (2003) 278(18):15661-15668.
42. LOHI J: Laminin-5 in the progression of carcinomas. Int. J Cancer. (2001) 94:763-767.
43. GIANNELLI G, ANTONACI S: Biological and clinical relevance of laminin-5 in cancer. Clin. Exp. Metastasis (2000) 18(6):439-443.
44. GAGNOUX-PALACIOS L, ALLEGRA M, SPIRITO F et al.: The short arm of the laminin γ2 chain plays a pivotal role in the incorporation of laminin-5 into the extracellular matrix and in cell adhesion. J. Cell Biol. (2001) 153(4):835-849.
45. MIZUSHIMA H, HIROSAKI T, MIYATA S, TAKAMURA H, MIYAGI Y, MIYAZAKI K: Expression of laminin-5 enhances tumorgenicity of human fibrosarcoma cells in nude mice. Jpn. J. Cancer Res. 93(6):652-659.
46. ANDERSON TD, FELDMAN M, WEBER RS, ZIOBER AF, ZIOBER BL: Tumor deposition of laminin-5 and the relationship with perineural invasion. Laryngoscope (2001) 111:2140-2143.
47. ONO Y, NAKANISHI Y, GOTOH M, SAKAMOTO M, HIROHASHI S: Epidermal growth factor receptor gene amplification is correlated with laminin-5 γ2 chain expression in oral squamous cell carcinoma cell lines. Cancer Lett. (2002) 175:197-204.
48. SKYLDBERG B, SALO S, ERIKSSON E et al.: Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst. (1999) 91(21):1882-1887.
49. LENANDER C, HABERMANN JK, OST A et al.: Laminin-5 gamma2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal. Cell. Pathol. (2001) 22(4):201-209.
50. GIANNELLI G, FRANSVEA E, BERGAMINI C, MARINOSCI F, ANTONACI S: Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin. Cancer Res. (2003) 9(10):3684-3691.
51. MCGOWAN K, VEITCH D, FINDELL P et al.: BMP-1 processing of laminin-5 controls migration of human epithelial cells. Ann. Meeting Soc. Invest. Dermatol. Chicago, USA (2000).
52. WOLZ RL, ZEGGAF C, STOCKER W, ZWILLING R: Thio containing compounds and amino acid hydroxamates as reversible synthetic inhibitors of astacus proteinase. Arch. Biochem. Biophys. (1990) 281(2):275-281.
53. YIALLOUROS I, VASSILIOU S, YIOTAKIS A, ZWILLING R, STOCKER W, DIVE V: Phosphinic acids, the first potent inhibitors of astacin, behave as extremely slow-binding inhibitors. Biochem. J. (1998) 331:375-379.
54. DANKWARDT SM, BILLEDEAU RJ, LAWLEY LK, ABBOT, SC, MARTIN RL, CHAN CS et al.: Solid-phase synthesis of di- and tripeptide hydroxamic acids as inhibitors of procollagen C-proteinase. Bioorg. Med. Chem. Lett. (2000) 10:2513-2516.
55. OVENS A, JOULE JA, KADLER KE: Design and synthesis of acidic dipeptide hydroxamate inhibitors of procollagen C-proteinase. J. Peptide Sci. (2000) 6:489-495.
56. ROBINSON LA, WILSON DM, DELAET NGJ, BRADLEY EK, DANKWARDT SM, CAMPBELL JA et al.: Novel inhibitors of procollagen C-proteinase, part 2: Glutamic acid hydroxamates. Bioorg. Med. Chem. Lett. (2003) 13:2381-2384.
57. DANKWARDT SM, ABBOT SC, BROKA CA, MARTIN RL, CHAN CS, SPRINGMAN EB et al.: Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase. Part 2: Solid-phase optimization of side chains. Bioorg. Med. Chem. Lett. (2002) 12:1233-1235.
58. BAILEY S, FISH PV, JAMES K, MCELROY A: Discovery of UK-383,367, a potent and selective non-peptidic inhibitor of procollagen C-proteinase for the treatment of dermal scarring. 227th American Chem. Soc. National Meeting. Anaheim, USA (2004) MEDI 13.
59. NATCHUS MG, BOOKLAND RG, LAUTERSWEILER MJ et al.: Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. J. Med. Chem. (2001) 44:1060-1071.
60. SUZUKI N, LABOSKY PA, FURUTA Y et al.: Failure of ventral body wall closure in mouse embryos lacking a procollagen C-proteinase encoded by BMP1, a mammalian gene related to Drosophila tolloid. Development (1996) 122:3587-3595.
61. HAJDUK PJ, SHUKER SB, NETTESHEIM DG et al.: NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailibility. J. Med. Chem. (2002) 45:5628-5639.
62. MACPHERSON LJ, BAYBURT EK, CAPPARELLI MP et al.: Discovery of CGS-27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. (1997) 40:2525-2532.
63. SINGH J, CONZENTINO P, CUNDY K et al.: Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitors. Bioorg. Med. Chem. Lett. (1995) 5:337-342.
64. SKOTNICKI JS, ZASK A, NELSON FC, ALBRIGHT JD, LEVIN JI: Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann. NY Acad. Sci. (1999) 878:61-72.